Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats

Hall, Melanie; Adin, Christopher A.; Borin-Crivellenti, Sofia; Rudinsky, Adam J.; Rajala‐Schultz, Päivi J.; Lakritz, Jeffrey; Gilor, Chen

doi:10.1016/j.domaniend.2014.12.001

Cited by 24 publications

(27 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In humans with type 2 DM, treatment with GLP‐1 analogues is associated with weight loss, whereas insulin glargine treatment is associated with weight gain . Weight loss was described in healthy cats during treatment with exenatide or liraglutide . In our study, a significant weight gain and increase in BCS were observed in cats of the placebo group, likely due to the anabolic effect of insulin treatment, but the increase was not significant in the exenatide ER group.…”

Section: Discussionmentioning

confidence: 47%

“…The DPP‐4 inhibitors were shown to decrease plasma glucagon concentration and to enhance insulin secretion in cats . Administration of exenatide, exenatide ER, or liraglutide caused glucose‐dependent insulin secretion, and a decrease in body weight occurred after the administration of exenatide and liraglutide in cats . A recent comparison of incretin‐based treatments in cats showed that exenatide and exenatide ER had more pronounced effects on insulin secretion than sitagliptin .…”

mentioning

confidence: 99%

“…9,10 Administration of exenatide, exenatide ER, or liraglutide caused glucose-dependent insulin secretion, and a decrease in body weight occurred after the administration of exenatide and liraglutide in cats. [11][12][13][14] A recent comparison of incretin-based treatments in cats showed that exenatide and exenatide ER had more pronounced effects on insulin secretion than sitagliptin. 15 Furthermore, exenatide ER was considered a better option than exenatide or sitagliptin because it is administered only once weekly and has fewer adverse effects.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus

Riederer

Zini

Salesov

et al. 2015

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundExenatide extended release (ER) is a glucagon‐like peptide‐1 analogue that increases insulin secretion, inhibits glucagon secretion and induces satiation in humans with type 2 diabetes mellitus. The use of exenatide ER is safe and stimulates insulin secretion in healthy cats.ObjectivesThe objective of this study is to assess the safety of exenatide ER and its effect on body weight, remission and metabolic control in newly diagnosed diabetic cats receiving insulin and a low‐carbohydrate diet.AnimalsThirty client‐owned cats.MethodsProspective placebo‐controlled clinical trial. Cats were treated with exenatide ER or 0.9% saline, administered SC, once weekly. Both groups received insulin glargine and a low‐carbohydrate diet. Exenatide ER was administered for 16 weeks, or in cats that achieved remission it was given for 4 weeks after discontinuing insulin treatment. Nonparametric tests were used for statistical analysis.ResultsCats in the exenatide ER and placebo groups had transient adverse signs including decreased appetite (60% vs. 20%, respectively, P = .06) and vomiting (53% vs. 40%, respectively, P = .715). Body weight increased significantly in the placebo group (P = .002), but not in cats receiving exenatide ER. Cats on exenatide ER achieved remission or good metabolic control in 40% or 89%, respectively, whereas in control cats percentages were 20% or 58% (P = .427 and P = .178, respectively).Conclusion and clinical importanceExenatide ER is safe in diabetic cats and does not result in weight gain. Our pilot study suggests that, should there be an additional clinically relevant beneficial effect of exenatide ER in insulin‐treated cats on rate of remission and good metabolic control, it would likely approximate 20% and 30%, respectively.

show abstract

Section: Discussionmentioning

confidence: 47%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus

Riederer

Zini

Salesov

et al. 2015

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…It is likely that the slow release and climb to steady-state concentrations seen in this study contribute to the apparent tolerance in cats. This is further supported by the presence of increased side effects with other GLP-1R agonists in cats with more rapid rise in plasma concentrations [24].…”

Section: Discussionmentioning

confidence: 88%

Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats

Rudinsky

Adin

Borin-Crivellenti

et al. 2015

Domestic Animal Endocrinology

Self Cite

View full text Add to dashboard Cite

“…Without an accurate indicator of long‐term glycemia (fructosamine or glycosylated hemoglobin), it is difficult to recommend a new definition that encompasses all of these stages. Although there are no comprehensive RI studies for BG in cats, multiple studies in adult healthy cats consistently show fasting BG do not exceed 126 mg/dL (7 mmol/L) . Thus, we propose that overt DM in cats be defined as documentation of a persistently increased fasting BG ≥ 126 mg/dL (7 mmol/L), supported by documentation of elevated fructosamine or glycosylated hemoglobin, regardless of clinical signs attributable to a pathologic excess of circulating glucose.…”

Section: Dm In Cats: Breaking Down the Type 2 Umbrellamentioning

confidence: 88%

What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters

Gilor

Niessen

Furrow

et al. 2016

Veterinary Internal Medicne

Self Cite

123

139

View full text Add to dashboard Cite

Diabetes Mellitus (DM) is a syndrome caused by various etiologies. The clinical manifestations of DM are not indicative of the cause of the disease, but might be indicative of the stage and severity of the disease process. Accurately diagnosing and classifying diabetic dogs and cats by the underlying disease process is essential for current and future studies on early detection, prevention, and treatment of underlying disease. Here, we review the current etiology‐based classification of DM and definitions of DM types in human medicine and discuss key points on the pathogenesis of each DM type and prediabetes. We then review current evidence for application of this etiology‐based classification scheme in dogs and cats. In dogs, we emphasize the lack of consistent evidence for autoimmune DM (Type 1) and the possible importance of other DM types such as DM associated with exocrine pancreatic disease. While most dogs are first examined because of DM in an insulin‐dependent state, early and accurate diagnosis of the underlying disease process could change the long‐term outcome and allow some degree of insulin independence. In cats, we review the appropriateness of using the umbrella term of Type 2 DM and differentiating it from DM secondary to other endocrine disease like hypersomatotropism. This differentiation could have crucial implications on treatment and prognosis. We also discuss the challenges in defining and diagnosing prediabetes in cats.

show abstract

Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats

Cited by 24 publications

References 33 publications

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus

Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats

What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters

Contact Info

Product

Resources

About